Parenteral Nutrition-Associated Liver Disease in Adult and Pediatric Patients
There are essentially 3 types of hepatobiliary disorders associated with parenteral nutrition (PN) therapy: steatosis, cholestasis, and gallbladder sludge/stones. Reported prevalence rates of PN-associated liver disease (PNALD) vary greatly, and there are distinct differences between adult and pedia...
Gespeichert in:
Veröffentlicht in: | Nutrition in Clinical Practice 2006-06, Vol.21 (3), p.279-290 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | There are essentially 3 types of hepatobiliary disorders associated with
parenteral nutrition (PN) therapy: steatosis, cholestasis, and gallbladder
sludge/stones. Reported prevalence rates of PN-associated liver disease
(PNALD) vary greatly, and there are distinct differences between adult and
pediatric patients. Various etiologic factors have been evaluated for
significance in contributing to PNALD, including enteral feeding history,
septic events, bacterial overgrowth, length of intestinal resection, and
prematurity/low birth weight. Etiologic factors specifically related to the PN
formulation or nutrient intake have also been evaluated, including excessive
calorie intake, dextrose-to-lipid ratio, amino acid dose, taurine deficiency,
IV fat emulsion (IVFE) dose, carnitine deficiency, choline deficiency, and
continuous vs cyclic infusion. Minor increases in serum
aminotransferase concentrations are relatively common in patients receiving PN
therapy and generally require no intervention. The primary indicator of
cholestasis is a serum conjugated bilirubin >2 mg/dL. When a patient
receiving PN develops liver complications, it is necessary to rule out all
treatable causes and minimize other risk factors. All potential hepatotoxic
medications and herbal supplements should be eliminated. Modifications to the
PN regimen that may be helpful include reduction of calories, reduction of
IVFE dose to |
---|---|
ISSN: | 0884-5336 1941-2452 |
DOI: | 10.1177/0115426506021003279 |